Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Eli Lilly’s COVID-19 antibody combination reduces risk of hospitalisations and death

High-risk patients treated with the two drugs had a 70% reduction in hospitalisation and death

- PMLiVE

Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine

Boosters will be designed to protect against new variants

- PMLiVE

What does the future hold for Medical Affairs?

Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.

Blue Latitude Health

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

regeneron headquarters

Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients

Monoclonal antibodies prevented 100% of symptomatic infections

- PMLiVE

UK study finds antibiotics azithromycin and doxycycline ineffective against COVID-19

PRINCIPLE study evaluated the commonly-used antibiotics in patients aged over 50

Wilmington Healthcare appoints new Head of Digital

Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.In his new role,...

Wilmington Healthcare

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

- PMLiVE

A happier new year?

Communicators need to remind us all why the pharmaceutical sector is so important

- PMLiVE

Moderna’s COVID-19 vaccine appears effective against UK and South Africa variants

However, vaccine has a six-fold reduction in neutralising antibodies against SA strain

- PMLiVE

UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains

FDA approved the antiviral drug for the treatment of hospitalised COVID-19 patients in October 2020

- PMLiVE

Merck ends its COVID-19 vaccine programme after disappointing early trial results

Immune responses were inferior to levels observed in recovered COVID-19 patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links